42.98  0.01 (0.02%)		09-27 16:00
Open: 42.98 High: 42.99 Volume: 6,703,315		Pre. Close: 42.97 Low: 42.97 Market Cap: 4,458(M)

Short term
Mid term
Targets	6-month :	50.44	1-year :	50.97
Resists	First :	43.18	Second :	43.63
Pivot price	42.82
Supports	First :	42.45	Second :	35.31
MAs	MA(5) :	42.93	MA(20) :	42.79
	MA(100) :	42.21	MA(250) :	39.71
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	29.2	D(3) :	27.8
RSI	RSI(14): 72.6
52-week	High :	52.22	Low :	22.89

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SYNH ] has closed below upper band by 8.8%. Bollinger Bands are 63.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 85 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	43.03 - 43.2	43.2 - 43.35
Low:	42.5 - 42.71	42.71 - 42.9
Close:	42.61 - 42.96	42.96 - 43.26

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Thu, 25 Apr 2024
Hedge Funds Are Betting On Syneos Health, Inc. (SYNH) - AOL

Fri, 19 Apr 2024
Here's Why You Should Hold on to Syneos Health (SYNH) for Now - Yahoo Movies Canada

Thu, 28 Sep 2023
Syneos Health Closes Transaction with Private Investment Firms - GlobeNewswire

Thu, 28 Sep 2023
It's official: Syneos Health goes private in $7.1B PE deal - MM+M Online

Fri, 22 Sep 2023
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos ... - Business Wire

Fri, 22 Sep 2023
Attention SYNH Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class ... - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	104 (M)
Shares Float	103 (M)
Held by Insiders	0.4 (%)
Held by Institutions	94.7 (%)
Shares Short	6,760 (K)
Shares Short P.Month	6,460 (K)

EPS	0.69
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	33.68
Profit Margin	1.3 %
Operating Margin	6.3 %
Return on Assets (ttm)	2.6 %
Return on Equity (ttm)	2 %
Qtrly Rev. Growth	0.4 %
Gross Profit (p.s.)	12.05
Sales Per Share	52.25
EBITDA (p.s.)	5.66
Qtrly Earnings Growth	-99 %
Operating Cash Flow	253 (M)
Levered Free Cash Flow	172 (M)

PE Ratio	61.4
PEG Ratio	41.6
Price to Book value	1.27
Price to Sales	0.82
Price to Cash Flow	17.62

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.